Piper Jaffray analyst Tyler Van Buren lowered his price target for Nektar Therapeutics to $100 citing increased expenses flowing the company’s Q4 results. However, the analyst believes the company’s broader immunology pipeline is advancing nicely. He keeps an Overweight rating on the shares.
https://thefly.com/landingPageNews.php?id=2872819
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.